Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: Shionogi, Fresenius Kabi Join July Approval Parade; Busy August Expected

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

You may also be interested in...



BMS Jumps Ahead With LAG-3 Melanoma Data

LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.

Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA

The latest drug development news and highlights from our US FDA Performance Tracker.

Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain

Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel